ストックスクリーナーアプリを入手
1.715
3.64%
0.065
Cardiff Oncology Inc (CRDF) 最新ニュース
Cardiff Oncology to present colorectal cancer trial data at ASCO - Investing.com
Cardiff Oncology to present colorectal cancer trial data at ASCO By Investing.com - Investing.com Canada
Cardiff Oncology to Present Updated Data on Onvansertib in RAS-Mutated Colorectal Cancer at ASCO 2026 - Quiver Quantitative
Updated metastatic colon cancer data gets ASCO oral slot - Stock Titan
Cardiff Oncology to Present Updated Phase 2 Data of - GlobeNewswire
H.C. Wainwright reiterates Cardiff Oncology stock rating at buy By Investing.com - Investing.com Canada
Cardiff Oncology (CRDF) price target decreased by 17.38% to 8.74 - MSN
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting - Sahm
Cardiff Oncology (CRDF) Unveils Promising Preclinical Data at AA - GuruFocus
Cardiff Oncology presents preclinical data on cancer drug combo By Investing.com - Investing.com South Africa
Cardiff Oncology presents preclinical data on cancer drug combo - Investing.com
In resistant breast cancer models, Cardiff combo drove tumor regression - Stock Titan
Cardiff Oncology (CRDF) CFO discloses initial holding of 500 common shares - Stock Titan
Cardiff Oncology (NASDAQ: CRDF) CFO awarded 486,650 stock options - Stock Titan
Cardiff Oncology (CRDF) CSO granted 300,000 stock options expiring 2036 - Stock Titan
Cardiff Oncology (CRDF) CFO receives 486,650 options at $1.58 strike - Stock Titan
Cardiff Oncology appoints Mani Mohindru as CEO - MSN
Momentum Shift: Is Cardiff Oncology Inc likely to announce a buyback2026 Breakouts & Breakdowns & Smart Swing Trading Techniques - baoquankhu1.vn
Cardiff Oncology Appoints Mani Mohindru as CEO and Expands Executive Team to Advance Cancer Drug Onvansertib - Minichart
Cardiff Oncology announces key leadership appointments to strengthen executive team for next phase of growth - marketscreener.com
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth - Bitget
Cardiff Oncology, Inc. Announces Management Appointments - marketscreener.com
Cardiff Oncology (CRDF) Appoints New Leadership Team - GuruFocus
Cardiff Oncology, Inc. Appoints Josh Muntner as Chief Financial Officer, Effective April 6, 2026 - marketscreener.com
Cardiff Oncology, Inc. Appoints Mani Mohindru as Chief Executive Officer - marketscreener.com
Cardiff Oncology appoints new CEO, CFO and COO - TipRanks
Form 8-KCurrent report - ADVFN
What is Wall Street’s view on Cardiff Onco (CRDF) Stock | Price at $1.58, Up 1.60%Stock Distribution - Cổng thông tin điện tử tỉnh Lào Cai
Cardiff Oncology: Market Dismisses Onvansertib's Potential In First-Line Colorectal Cancer - Seeking Alpha
Short Interest in Cardiff Oncology, Inc. (NASDAQ:CRDF) Declines By 9.4% - 富途牛牛
CRDF Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Cardiff Oncology Formalizes Executive Departures Amid Strategic Review - TipRanks
Cardiff Oncology Inc. (CRDF) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Cardiff Oncology director Dr. Erlander resigns - TradingView — Track All Markets
Cardiff Oncology (CRDF) CEO awarded 600,000 options at $1.62 strike - Stock Titan
[8-K] Cardiff Oncology, Inc. Reports Material Event - Stock Titan
CRDF SEC FilingsCardiff Oncology Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Jobs Data: Can Cardiff Oncology Inc reach all time highs this yearTreasury Yields & Daily Momentum Trading Reports - baoquankhu1.vn
Noble Financial Issues Optimistic Estimate for CRDF Earnings - MarketBeat
Growth Review: What is the PEG ratio of Cardiff Oncology Inc2026 Buyback Activity & Risk Controlled Daily Plans - baoquankhu1.vn
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), QT Imaging Holdings (QTI) and Cardiff Oncology (CRDF) - The Globe and Mail
Vanguard (NASDAQ: CRDF) reports 0 shares after Jan 12, 2026 realignment - stocktitan.net
Craig-Hallum reiterates Buy on Cardiff Oncology stock, $10 target By Investing.com - Investing.com Canada
Craig-Hallum reiterates Buy on Cardiff Oncology stock, $10 target - Investing.com
William Blair reiterates Cardiff Oncology stock rating on drug data By Investing.com - ca.investing.com
H.C. Wainwright reiterates Cardiff Oncology stock rating at buy - Investing.com
Cardiff Oncology Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
CRDF: Onvansertib plus FOLFIRI+BEV achieved a 72% response rate and strong PFS in RAS mutated CRC - TradingView
Cardiff Oncology Showcases Onvansertib: 72% ORR Signal in Phase II RAS-Mutant mCRC Webinar - MarketBeat
Cardiff Oncology Inc to Host KOL Webinar Transcript - gurufocus.com
Published on: 2026-03-26 02:49:36 - baoquankhu1.vn
1.09%
0.42%
大文字化:
|
ボリューム (24 時間):